Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study

Background & Aims: Atezolizumab plus bevacizumab (A+B) is a standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). However, optimal sequencing strategies after A+B failure remain undefined. Methods: LEVIATHAN is a multicentre, observational study evaluating efficac...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Pasquale Lombardi, Jung Sun Kim, Giulia F. Manfredi, Ciro Celsa, Claudia A.M. Fulgenzi, Antonio D’Alessio, Bernardo Stefanini, Niraj C. Doshi, Emily Warmington, Thomas U. Marron, Matthias Pinter, Bernhard Scheiner, Beodeul Kang, Ho Yeong Lim, Wei-Fan Hsu, Brooke Wietharn, Marianna Silletta, Alessandro Parisi, Chun-Yen Lin, Andrea Dalbeni, Gianluca Masi, Martin Schönlein, Johann von Felden, Fabio Piscaglia, Peter R. Galle, Masatoshi Kudo, Tiziana Pressiani, Lorenza Rimassa, Mario Pirisi, Giuseppe Cabibbo, Hong Jae Chon, David J. Pinato
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-12-01
coleção:	JHEP Reports
Assuntos:	Hepatocellular carcinoma Lenvatinib Sorafenib Treatment sequencing Atezolizumab-bevacizumab resistance
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2589555925002770
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!